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Abstract 
Background: The Uganda National Malaria Control Programme recommends the use of intermittent preventive ther-
apy in pregnancy with sulfadoxine/pyrimethamine (SP) to prevent malaria, however, there is overwhelming evidence 
of low uptake of this intervention. This study, therefore, sought to examine the factors associated with taking two or 
more doses of therapy among women who had had the most recent live birth.
Methods: This was a secondary data analysis of the 2014 Malaria Indicator Survey dataset. The outcome was the use 
of two or more doses of SP for the most recent live birth while independent variables included; age, highest educa-
tion attained, residence (rural and urban), use of radio and community health teams for malaria related messages, 
knowledge of taking SP and use of LLINS to prevent malaria, household wealth, skilled attendant seen at ANC and 
number of children the woman has.
Results: Of the 1820 women included in the final analysis, 822 (45.16 %) women took two or more doses of SP. 
Women who knew that this therapy was used to prevent malaria and those who had been seen by a skilled atten-
dant were 10.72 times [Adjusted OR (95 % CI): 10.72 (7.62–15.08), p-value = 0.001] and 3.19 times [Adjusted OR (95 % 
CI): 3.19 (1.26–8.07), p-value  = 0.015] more likely to take at least two doses as compared to those who did not know 
about this therapy and those seen by unskilled attendants, respectively.
Conclusion: This study shows that knowledge among women that SP is a medication used for malaria prevention 
during pregnancy increases the uptake of two or more doses of this therapy among pregnant women. This highlights 
the importance of behaviour change communication focused on IPTp uptake that can be complemented by having 
skilled personnel attending to pregnant women at the antenatal clinic.
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Background
Malaria is hyper-endemic in over 90  % of Uganda’s 
regions [1] and, therefore, still remains a disease of public 
health importance. The greatest burden of this disease is 
born by populations who have either not yet acquired full 
immunity to malaria, like children under 5 years, or those 
whose immunity has been suppressed, for example by 
physiological conditions like pregnancy among women 
[1, 2].
The National Malaria Control Programme recognizes 
the significance of increasing the coverage of the most 
important malaria control interventions and use espe-
cially in these two vulnerable populations. In the past dec-
ade, with increasing funding, there has been a scale-up of 
interventions especially on LLIN coverage, case manage-
ment, and intermittent preventive therapy in pregnant 
women (IPTp) using sulfadoxine/pyrimethamine (SP). 
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Such efforts have included the shift to universal LLIN 
coverage [1, 3], with a mass campaign in 2013, increas-
ing availability of rapid diagnostic tools (RDTs) and 
artemisinin-based combination therapy (ACT) at health 
facilities for case management and IPTp using SP among 
pregnant mothers at the ante-natal clinics(ANC) [1]. The 
national guidelines recommend at least four ANC visits 
for all pregnant mothers in line with the WHO guidelines 
[4, 5], where they receive an LLIN on their first visit, and 
also take SP at each of the visits [6].
So far, there has been success in LLIN coverage and 
use, with 90  % of households owning at least an LLIN 
and 75  % of pregnant women sleeping under one the 
night before the survey. There has also been consider-
able improvement regarding case management where 
mothers of 82 % of children with fever, sought treatment 
or advice and 87 % of children with a fever were treated 
with an artemisinin-based combination therapy (ACT). 
However, this success has noticeably been slow with IPTp 
uptake among pregnant women, with 89  % of women 
receiving one or more doses of SP, and this reduces to 
45 % who received two or more doses and further down 
to 25 %who received three or more doses [7]. This trend 
is not only peculiar to Uganda, but has also been reported 
in other African countries [8, 9].
This is of concern in the fight against malaria among 
pregnant, a disease whose consequences are clearly doc-
umented to include anaemia in mothers, still birth, early 
neonatal death, pre-term delivery, intra-uterine growth 
retardation and low birth weight in infants [10–12]. The 
malaria prevention benefits of taking SP as IPTp to avoid 
such adverse events are known [13, 14] and, therefore, its 
scale up is of great importance. To reduce the burden of 
malaria in pregnancy, a combination of all these inter-
ventions should be implemented to protective population 
coverage levels [5, 6] and the NMCP has adopted this 
strategy with the aim of achieving 85 % intervention cov-
erage in the populations at risk by 2020 [1].
Therefore, using the Uganda 2014 malaria indicator 
survey (MIS 2014), the objectives of this secondary anal-
ysis was to determine the factors associated with taking 
two or more doses of SP among women who had had a 
live pregnancy 2  years prior to the survey. This would 
give an understanding of individual related factors that 
lead to the low uptake of the IPTp in this setting thereby 
contributing to the design and implementation of evi-
dence based strategies to improve the SP usage coverage.
Methods
This was a secondary data analysis using a dataset from 
the recently concluded 2014 Uganda Malaria Indicator 
Survey.
Description of the malaria indicator Survey (MIS) dataset
The survey was conducted during the months of Decem-
ber 2014 and January 2015 [7]. Households were selected 
using a stratified two-stage cluster design from 210 enu-
meration areas, representing all the regions of the coun-
try with 44 in urban areas and 166 in rural areas. An EA 
was defined as a natural village in rural areas and a city 
block in urban areas. In the first stage, 20 sampling strata 
(derived from 10 regional domains: Central 1 and 2, East 
Central, Kampala, Mid-Northern, Mid-Western, Mid-
Eastern, South-Western and West Nile) were created and 
EAs were selected independently from each stratum by a 
probability-proportional-to-size selection. In the selected 
EAs, a complete listing of households and a mapping 
exercise was conducted in November 2014, with the 
resulting list of households serving as the sampling frame 
for the selection of households in the second stage. The 
average EA size was 94 households in urban areas and 77 
households in rural areas, with an overall average size of 
80 households per EA. In the second stage of the selec-
tion process, 28 households were selected in each EA by 
equal probability systematic sampling. A total of 5802 
households were selected for the 2014 MIS, of which 
5494 were occupied. Of the occupied households, 5345 
were successfully interviewed, yielding a response rate 
of 97  %. The response rate among households in rural 
areas was slightly higher (98  %) than the response rate 
in urban areas (96 %). The main reason for non-response 
was failure to find individuals at home despite up to four 
repeated visits to the household. Informed consent was 
obtained from all participating heads of households and 
women of child-bearing age in the households that par-
ticipated in the survey.
For the specifics of this study, a women’s question-
naire administered to all women aged 15–45  years in a 
selected household was used to collect data on women’s 
background characteristics (age, education,); reproduc-
tive history (number of births, postnatal care etc.); IPTp 
using SP for malaria during recent pregnancies in the 
last 2 years; information on knowledge of LLIN use and 
malaria.
Study variables
The dependent variable of interest was a woman who 
had taken two or more doses of SP among those that had 
had a pregnancy 2 years preceding the survey. Independ-
ent variables included; age, highest education attained, 
residence (rural and urban), use of radio and community 
health teams for malaria related messages, knowledge of 
taking SP to prevent malaria, knowledge of use of LLINs 
to prevent malaria, use of an LLIN, wealth, attendant 
skill seen at ANC (skilled attendants include: doctors, 
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midwives/nurses and clinical officers) and number of 
children the woman has.
Data analysis
Stata version 14 (Statcorp, College Station, Texas, USA) 
was used for all data analysis. For this study, we used the 
individual recode DHS dataset of the 2014 MIS. In order 
to cater for sampling variations, only weighted survey 
data is presented in this manuscript. This is because of 
the non-proportional allocation of the sample in the dif-
ferent regional domains at the second sampling stage 
(28 households were selected in each EA by equal prob-
ability systematic sampling), resulting into a sample that 
was not self-weighting. Weighting factors were calculated 
based on the population of the selected regional domains 
and added to the MIS datasets so that any results with 
the regional weight factored into it would be representa-
tive at the national and regional level as well as the sur-
vey domain level. Details of how the weighting for the 
different regional domains was estimated are available 
in the 2014 MIS report [7]. The distributions of study 
participant’s baseline characteristics were presented as 
frequencies with respective proportions. A multivari-
ate logistic regression model with a survey function was 
used to assess for the factors associated with the use of at 
least two or more doses of SP to initially derive the crude 
and then the adjusted odds ratio with the respective con-
fidence interval. In all analyses, a p-value of  <0.05 was 
taken as statistically significant.
Results
Overall, 1820 women, who had had a live birth in the 
2  years prior to the survey were included in the final 
analysis (Fig.  1). As shown in Table  1, the majority of 
the participants were in the age category of 25–34 years 
(43.49  %), closely followed by those between 15 and 
24  years (41.95  %) and lastly those above 35  years 
(14.56 %). Women with primary education (60.26 %) and 
those from rural setting (82.80 %), were the majority for 
highest education level attained and residence respec-
tively. Overall household wealth and region of origin 
were more or less with a similar distribution with the 
exception of those that originated from Kampala that had 
the least number of women at 4.64 %.
The use of two or more doses of SP for IPTp
Of the 1820 women, 1771 (97.31  %) attended at least 
one ante-natal care visit and of these 97.71  % received 
27,539 individuals included in the survey 
from 5,345 households
22, 217 individuals were not women of child 
bearing age (15-45 years)
5,322 women of child bearing age 
(15-45 years)
3,502 women did not have a live birth 
two years preceding the survey
1,820 had a live birth in two years 
preceding the survey
822 women took two or more doses of IPTp 
during the last pregnancy
998 women did not take two or more 
doses of IPTp during the last pregnancy
Fig. 1 Study profile
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SP during their antenatal visit, 1.77 % from another visit 
to the facility and <1  % (0.53  %) obtained theirs from 
another source. Overall, 822 of the 1820 (45.16 % [42.88–
47.45]) women of child bearing age, who had had a live 
birth 2  years preceding the survey, took two or more 
doses of SP.
Among factors considered, only 982 (54.00  %) of 
women knew that SP was used as a medication to pre-
vent malaria, with the majority, 649 (78.97  %), of these 
among those who had taken at least two doses of SP. 
Therefore, the odds of taking two or more doses of SP 
among women who were knowledgeable regarding SP 
was 10.72 times greater as compared to those who did 
not know [Adjusted OR (95  % CI): 10.72 (7.62–15.08), 
p-value  =  0.001] (Table  2). The same was observed 
among women who had been seen by a skilled attendant 
at ante-natal clinic, with the odds of taking at least two 
doses of SP at 3.19 times greater as compared to women 
who had been seen by an unskilled attendant [Adjusted 
OR (95  % CI): 3.19 (1.26–8.07), p-value =  0.015]. Simi-
larly women who had three or more children were 1.68 
times more likely to take SP [Adjusted OR (95  % CI): 
1.68 (1.04–2.70), p-value = 0.033], however, the opposite 
occurred among women older than 35 years, as they were 
38 % less likely to take SP as compared to those between 
15 and 24 years [Adjusted OR (95 % CI): 0.62 (0.38–0.99), 
p-value = 0.043]. The rest of the variables were not statis-
tically significant.
Discussion
The major finding that women who knew that taking SP 
to prevent malaria were over ten times more likely to take 
two or more doses of SP is not surprising considering that 
the majority, close to 80 %, were knowledgeable regarding 
the use of SP. This finding is vital especially in this con-
text where just over half the number of the women inter-
viewed knew that SP was a medication used to prevent 
malaria during pregnancy. This lack of knowledge could 
possibly be due to a deficiency in behavioural change 
communication messages that are primarily meant to be 
delivered at the ante-natal clinic before the medication is 
prescribed [15, 16]. Of note, this result is in the backdrop 
that nearly almost all of the women interviewed attended 
ante-natal clinic with the major if not overall source of 
SP from the same clinics, an indirect indication that SP is 
mostly available at these facilities.
In contrast, this study has shown that the knowledge 
of the use of long-lasting insecticide-treated bed nets 
(LLIN) among pregnant women is at 80  %, a 35 point 
increase from the 45 % who took two or more doses of SP, 
a finding that has already been reported elsewhere [17]. 
This is despite the fact that both these interventions are 
administered in the same health facility at the ante-natal 
clinic in accordance with the national guidelines when 
on the first ANC visit, mothers are meat to receive an 
LLIN and also take their first dose of SP, usually at the 
earliest opportunity of the start of the second trimes-
ter [1]. Therefore, one way to improve the knowledge of 
IPTp as a malaria prevention medication would be to add 
IPTp malaria prevention messages to the already suc-
cessful LLINs’ messages, packaged together, especially 
for pregnant women attending ante-natal clinics. This is 
an important aspect, considering that for women to be 
motivated to seek SP for IPTp, it is paramount that they 
know this therapy is essential for use for malaria preven-
tion, just like LLINs, in pregnancy and it is available free 
of charge at ante-natal clinics [15, 18].
The finding that more women who have more than 
three children know the use of SP, possibly due to greater 
exposure to the messages, and are therefore significantly 
Table 1 Women’s baseline characteristics
a Education missing 9
Characteristic Distribution of participants
Total population N = 1820 Percentage
Age categories (years)
 15–24 763 41.95
 25–34 792 43.49
 >35 265 14.56
Highest education attaineda
 No education 294 16.25
 Primary 1091 60.26
 Secondary 363 20.06
 Higher 62 3.43
Residence
 Urban 313 17.20
 Rural 1507 82.80
Region
 Central 1 235 12.92
 Central 2 174 9.54
 East central 215 11.80
 Kampala 84 4.64
 Mid-North 193 10.61
 Mid-Western 212 11.65
 Mid-Eastern 189 10.36
 North-East 178 9.78
 South-Western 194 10.66
 West-Nile 146 8.04
Wealth
 Poorest 413 22.69
 Poorer 404 22.24
 Middle 350 19.22
 Richer 323 17.72
 Richest 330 18.13
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more likely take at least two doses of SP and also that 
women who are older than 35 years are less likely to take 
it, is an indication that these messages could perhaps be 
emphasized among women with a parity of <3 or those 
older than 35 years, respectively. Even with this evidence, 
there is still the possibility that women who took SP were 
the ones who had experienced its benefits and, there-
fore, knew of its usefulness in prevention of malaria. This 
Table 2 Factors associated with taking two or more doses of ITPp
CHT community health teams, ANC antenatal clinic
* Statistically significant at p < 0.05
a Adjusted for age, highest education attained, residence (rural and urban), use of radio and community health teams for malaria related messages, knowledge of 
taking SP was used to prevent malaria, knowledge of use of LLINs to prevent malaria, household wealth, attendant seen at ANC and number of children the woman 
has
b Skilled attendants (doctors, midwives/nurses and clinical officers)
Variable Took two or more doses of IPTp Crude OR (95 % CI) Adjusted OR (95 % CI)a p-value
Yes No
Age categories (years)
 15–24 326 (39.68) 437 (43.81) 1 1
 25–34 393 (47.83) 398 (39.91) 1.32 (1.06–1.65) 0.79 (0.53–1.17) 0.233
 >35 103 (12.48) 162 (16.28) 0.85 (0.62–1.15) 0.62 (0.38–0.99) 0.043*
Highest education attained
 No education 21 (14.72) 174 (17.52) 1 1
 Primary 449 (54.83) 642 (64.75) 1.01 (0.77–1.32) 0.84 (0.56–1.27) 0.402
 Secondary 207 (25.26) 156 (15.76) 1.91 (1.32–2.75) 1.11 (0.62–1.99) 0.728
 Higher 43 (5.19) 20 (1.97) 3.14 (1.64–6.00) 1.62 (0.73–3.57) 0.234
Residence
 Urban 158 (19.16) 155 (15.58)
 Rural 664 (80.84) 843 (84.42) 0.78 (0.57–1.06) 1.03 (0.63–1.70) 0.896
Heard malaria messages on radio
 No 100 (18.42) 131 (2.10)
 Yes 441 (81.58) 461 (77.90) 1.26 (0.88–1.79) 1.07 (0.70–1.64) 0.764
Heard malaria messages from CHT
 No 345 (64.20) 361 (61.50)
 Yes 192 (35.80) 226 (38.50) 0.89 (0.64–1.24) 0.86 (0.60–1.23) 0.402
Knowledge of taking IPTp
 No 173 (21.03) 664 (66.59)
 Yes 649 (78.97) 333 (33.41) 7.49 (5.69–9.84) 10.72 (7.62–15.08) 0.001*
Knowledge of use of bed net
 No 155 (19.67) 192 (20.84)
 Yes 635 (80.33) 728 (79.16) 1.08 (0.81–1.42) 1.15 (0.74–1.77) 0.536
Wealth
 Poorest 167 (20.29) 246 (24.67) 1 1
 Poorer 183 (22.27) 222 (22.21) 1.22 (0.91–1.63) 1.16 (0.72–1.87) 0.534
 Middle 143 (17.40) 207 (20.71) 1.02 (0.72–1.45) 0.73 (0.45–1.19) 0.211
 Richer 148 (18.04) 174 (17.46) 1.26 (0.84–1.88) 1.29 (0.71–2.33) 0.404
 Richest 181 (22.00) 149 (14.94) 1.79 (1.23–2.60) 0.96 (0.51–1.81) 0.904
Attendant seen at ANC
 Unskilled attendant 16 (1.94) 67 (6.69)
 Skilled attendantb 806 (98.06) 931 (93.31) 3.62 (1.61–8.13) 3.19 (1.26–8.07) 0.015*
Number of hildren
 One 143 (17.35) 212 (21.28) 1 1 0.521
 Two 149 (18.08) 174 (17.40) 1.27 (0.91–1.78) 1.19 (0.70–2.04) 0.033*
 More than three 531 (64.56) 612 (61.31) 1.29 (1.00–1.66) 1.68 (1.04–2.70)
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reverse-causality phenomenon is a recognized weakness 
of cross sectional studies like the MIS, because it is not 
easy to determine the chronology of events as both out-
come and factors associated are measured at the same 
time.
Another well known finding from this analysis was that 
women who had been seen by a skilled health worker 
(medical doctor, clinical officer and nurse/midwife) were 
close to three times more likely to take at least two doses 
of SP. This could be because such workers understand 
the usefulness of appropriate delivery of IPTp malaria 
prevention messages, in addition to correct prescription, 
highlighting the importance to improve training of all 
personnel who attend to pregnant women, as suggested 
in other studies [19, 20].
The strength of these findings lies in the fact that a large 
and representative unbiased national sample of women 
was used, captured in the 2014 MIS. However, there is 
the weakness that some factors associated with low IPTp 
uptake were not considered in this analysis since it relied 
only on individual related variables collected during the 
survey, leaving out those related to the health system and 
service providers [21].
Conclusion
The knowledge that SP is a medication used for malaria 
prevention during pregnancy is a strong driver of the 
uptake of at least two or more doses of SP. This could 
be one of the plausible reasons for the low coverage 
of this intervention and, therefore, it is important to 
place emphasis on behaviour change messages directed 
towards the use of SP in combination with LLINs at 
ante-natal clinics, coupled with training attending staff 
on how to deliver such messages in a simple and under-
standable way. These findings are generalizable to the 
Ugandan context as the MIS sample size was large and 
sample from all regions of the country, however, since 
this analysis was dependant on MIS collected vari-
ables, further studies to explore both health system and 
health provider factors that impact on IPTp usage are 
recommended.
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